Cardiac toxicity of cancer treatment regimes in children and adolescents: Physiopathology, clinical data and the paediatric oncologist's point of view;Toxicité cardiaque des traitements du cancer chez l'enfant et l'adolescent: Physiopathologie, données cliniques et point de vue de l'oncopédiatre

Bulletin du Cancer

Volumn 91, Issue SPEC. ISS., 2004, Pages

  Pein, François ^a   Iserin, Laurence ^b   De Vathaire, Florent ^c   Lemerle, Jean ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c INSERM   (France)

Author keywords

Adolescent; Cancer; Cardiac toxicity; Childhood; Sequellae

Indexed keywords

AMSACRINE; CYCLOPHOSPHAMIDE; FLUOROURACIL; TUBULIN;

ADOLESCENT; BEHAVIOR MODIFICATION; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CHILD; CHILDHOOD CANCER; CHILDHOOD LEUKEMIA; CYTOTOXICITY; DATA ANALYSIS; ENDOTHELIUM CELL; HEART VENTRICLE HYPERTROPHY; HUMAN; LIFESTYLE; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; SIDE EFFECT; SUDDEN DEATH;

ADOLESCENT; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; HEART; HEART DISEASES; HUMANS; NEOPLASMS; RADIATION INJURIES; SURVIVORS;

EID: 10044245126     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Pein F, Vassal G, Sakiroglu O, et al. Pediatric aspects of anthracycline cardiotoxicity and practical implications for prevention. Arch Pediatr 1995; 2: 988-99.
2. Bleyer WA. The impact of childhood cancer on the US and the world. CA Cancer J Clin 1990; 40: 355-67.
3. Pein F, Sakiroglu O, Dahan M, et al. Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br J Cancer 2004 Published online on 2004, May 25.
4. Carlson RG, Mayfield WR, Norman S, et al. Radiation-associated heart disease. Chest 1991; 99: 538-45.
5. Hull M, Morris P, Pepine, et al. Valvular dysfunction and carotid, subclavian and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA 2003; 290: 2831-7.
6. Strumberg D, Brugge S, Korn MW, et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol 2002; 13: 229-36.
7. Lee AY, Levine MN. The thrombophilic state induced by therapeutic agents in the cancer parients. Semin Thromb Hemost 1999; 25: 137-45.
8. Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol 1993; 11: 1199-203.
9. Hancock S, Hoppe R. Long-rerm complications of treatment and causes of mortality after Hodgkin's disease. Semin Radiat Oncol 1996; 6: 225-42.
10. Tolba KA, Deliargyris EN. Cardiotoxicity of cancer therapy. Cancer Invest 1999; 17: 408-22.
11. 2+ binding and lipid peroxydation but depresses myocardial function. Am J Physiol 1986; 250: 419-25.
12. Bu'Lock FA, Gabriel HM, Oakhill A, et al. Cardioprotection by ICRF-187 against high dose anthracyclin toxicity in children with malignant disease. Br Heart 1993; 70: 185-8.
13. Billingham ME, Masek MA. The pathology of anthracycline cardiotoxicity in children, adolescent and adults. In: Bricker JT, Green DM, D'Angio GJ, editors. Cardiac toxicity after treatment for childhood cancer. New York: Wiley-Liss, 1993.
14. Lipshultz SE, Rifai N, Sallan SE, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 1997; 96: 2641-8.
15. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-7.
16. Solymar L, Marky I, Mellander L, et al. Echocardiographic findings in children treated for malignancy with chemotherapy including adriamycin. Pediatr Hematol Oncol 1988; 5: 209-16.
17. Lipshultz SE, Lipsitz SR, Mone SM, et al. Left ventricular structure and function eleven years after doxorubicin treatment for childhood leukemia: Is this a restrictive cardiomyopathic process? J Am Coll Cardiol 1995; 32525(A): 54.
18. Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4 to 20 years after completing anthracyclin therapy. JAMA 1991; 266: 1672-7.
19. Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324: 808-15.
20. Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995; 332: 1738-43.
21. Silber JH, Jakacki RI, Larsen RL, et al. Forecasting cardiac function after anthracyclines in childhood: the role of dose, age and gender. In: Bricker JT, Green DM, D'Angio GJ, editors. Cardiac toxicity after treatment for childhood cancer. New York: Wiley-Liss, 1993.
22. Larsen RL, Jakacki RI, Vetter VL, et al. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol 1992; 70: 73-7.
23. Hausdorf G. Late effects of anthracycline therapy in childhood: evaluation and current therapy. In: Bricker JT, Green DM, D'Angio GJ, editors. Cardiac toxicity after treatment for childhood cancer. New York: Wiley Liss, 1993.
24. Silber JH, Cnaan A, Clark BJ, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004; 22: 820-8.
25. Lipshultz SE, Lipsitz SR, Sallam SE, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 2002; 20: 4517-22.
26. Shapira J, Gotfried M, Lishner M, et al. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation. Cancer 1990; 15: 870-3.
27. Casper ES, Gaynor JJ, Hajdu SI, et al. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer 1991; 68: 1221-9.
28. Zalupski M, Metch B, Balcerzak S. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst 1991; 83: 926-32.
29. Wexler LH, Andrich MP, Venzon D. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 1996; 14: 362-72.
30. Steinherz LJ, Graham T, Hurwitz R, et al. Guidelines for cardiac monitoring of children during and after anthracycline chemotherapy: report of the cardiologic committee of the children's cancer study group. Pediatrics 1992; 89: 942-9.
31. Lipshultz SE, Sanders AP, Goorin AM, et al. Monitoring for anthracycline cardiotoxicity. Pediatrics 1994; 93: 443-7.
32. Smibert E, Carlin JB, Vidmar S, et al. Exercise echography reflects cumulative anthracycline exposure during childhood. Pediatr Blood Cancer 2004; 42: 556-62.
33. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004 May 17, Epub ahead of print.
34. Colan SD, Parness IA, Spevak PJ, et al. Development modulation of myocardial mechanics: age-and growth-related alterations in afterload and contractility. J Am Coll Cardiol 1992; 19: 619-29.
35. Lipshultz SE, Colan SD. The use of echocardiography and holter monitoring in the assessment of anthracyclin-treated patients. In: Bricker JT, Green DM, D'Angio GJ, editors. Cardiac toxicity after treatment for childhood Cancer. New York: Wiley-Liss, 1993.
36. Henry WL, Gardin JM, Ware JH. Echographic measurement in normal subjects from infancy to old age. Circulation 1980; 62: 1054-61.
37. Hequet O, Le QH, Moullet I, et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol 2004; 22: 1864-71.
38. Gottdiener JS, Applebaum FR, Ferrans VJ, et al. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981; 141: 758-63.
39. Mandel EM, Lewinski U, Djaldetti M. Vincristine-induced myocardial infarction. Cancer 1976; 36: 1979-82.
40. Arbuck S, Strauss H, Rowinsky E, et al. A reassessment of cardiac toxicity associated with taxol. J Natl Cancer Inst 1993; 15: 117-30.
41. Ferrero JM, Magné N, Largillier R, et al. Tolerance cardiaque des associations paclitaxel-anthracyclines dans le cadre de la prise en charge du cancer du sein. Bull Cancer 2003; 90: 219-26.
42. Tsavaris N, Kosmas C, Vadiaka M, et al. Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy: a survey of 427 patients. Med Sci Monit 2002; 8: 151-7.
43. Wang WS, Hsieh RK, Chiou TJ. Toxic cardiogenic shock in a patient receiving weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin. Jpn J Clin Oncol 1998; 28: 551-4.
44. Oberlin O, Habrand JL, Zucker JM. No benefit of ifosfamide in Ewing's sarcoma: a non randomized study of the French Society of Pediatric Oncology. J Clin Oncol 1992; 10: 1407-12.